Developer docs
API playgroundTry for free, no card

Search company profiles

Celltrion Pharm

Full company profile

uuid0006mqe

Namestring
Celltrion Pharm
Legal namestring
주식회사 셀트리온제약 (Celltrion Pharm, Inc.)
Websiteurl
celltrionph.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

Celltrion Pharm, Inc. (셀트리온제약, KOSDAQ: KS200026) is a South Korea-based pharmaceutical manufacturer founded in 2000 and operating as a publicly listed subsidiary of Celltrion Group since 2009. The company produces and sells a portfolio of 12 biosimilar products and a broad line of chemical pharmaceuticals across autoimmune disease, oncology, allergy, liver disease, and cardiovascular therapeutic areas. Its flagship biosimilars include Remsima (world's first infliximab biosimilar), Remsima SC (world's first subcutaneous infliximab biosimilar), Truxima (rituximab), Herzuma (trastuzumab), and Vegzelma (bevacizumab); the chemical portfolio is anchored by Godex, the #1 outpatient liver-treatment brand in Korea. The company also operates a CMO business for oral solid dosage and PFS biopharmaceutical manufacturing under FDA, EMA, PMDA, and ANVISA GMP certifications.

Celltrion Pharm's technology platform spans biosimilar cell-line and process development, antibody-drug conjugate (ADC) research, subcutaneous and autoinjector formulation know-how, and nano/microsphere drug delivery systems. Manufacturing is concentrated at the GMP-certified Cheongju plant (OSD and PFS) and the Jincheon plant (chemical products), with research based at the Songdo Global Biotech Research Center. The company sells exclusively through Korean domestic channels — nine regional branch offices, medical representative coverage of hospitals and clinics, and a dedicated e-order system for registered pharmaceutical distributors — with end customers being healthcare providers and pharmacies whose purchases are reimbursed under the Korean National Health Insurance system.

In FY2025, Celltrion Pharm reported record revenue of 536.4 billion KRW, the first time the company exceeded 500 billion KRW in annual sales, supported by 1,006 employees. The company's commercial model is a sales-led enterprise field-sales motion with academic symposia, with revenue generated through prescription pharmaceutical sales, CMO services, and a regulated NHI pricing framework. Celltrion Group retains majority ownership and strategic oversight.

Short descriptiontext

Celltrion Pharm is a South Korea-based, KOSDAQ-listed pharmaceutical manufacturer selling a portfolio of 12 biosimilars and chemical drugs to Korean hospitals, clinics, and pharmacies through medical representatives and distributors, supported by globally GMP-certified manufacturing facilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCheongju, South Korea
HQ citystring
Cheongju
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biosimilar pharmaceuticals, chemical pharmaceuticals, contract manufacturing, drug delivery systems, antibody drug conjugates
Industry4 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Biosimilar Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Biosimilar Drug Sales
TypeOne Time License
Description

Sale of biosimilar pharmaceutical products including Remsima, Truxima, Herzuma, Vegzelma, Yuplima, and other autoimmune/cancer treatments in Korean domestic market

celltrionph.com
2Chemical Drug Sales
TypeOne Time License
Description

Sale of chemical pharmaceutical products including cardiovascular, endocrine, digestive, antibiotic treatments. Major product Godex leads liver treatment market. Achieved first 500 billion KRW annual sales milestone.

celltrionph.com
3CMO Services
TypeProfessional Services
Description

Contract manufacturing services for OSD (oral solid dosage) and PFS (pre-filled syringe) formulations under global GMP standards for domestic and international partners

celltrionph.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Supply Chain, Technology or R&D, Marketing or Sales, Personnel
Pricing details1 tier
1Omriqlo 150mg AI - same price as PFS formulation
ModelOtherBilling cadencePay-as-you-go
Notes

Price: 173,404 KRW per unit; identical pricing between AI and PFS formulations allows physicians to choose device based on patient needs without price constraints

celltrionph.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Celltrion Pharm manufactures and sells biosimilar and chemical pharmaceutical products in the Korean domestic market, with a portfolio of 12 biosimilars (including Remsima, Truxima, Herzuma, Vegzelma) and chemical drugs (including Godex for liver disease and combination antihypertensives). The company also provides contract manufacturing (CMO) services for oral solid dosage (OSD) and pre-filled syringe (PFS) formulations to domestic and international pharmaceutical partners under global GMP standards.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Remsima cumulative sales of 3,008 billion KRW as of December 2025
+2 more records
Product overview1 text field

Celltrion Pharm is a Korean pharmaceutical company offering both chemical and biosimilar products, with a portfolio of 12 biosimilar products and diverse chemical medications across therapeutic areas including cardiovascular, endocrine, digestive, and liver diseases. The chemical portfolio includes market-leading products like Godex for liver disease and combination antihypertensives like Treble Tab and Idaldipine. The biosimilar portfolio features world-first antibody biosimilars including Remsima (infliximab), Truxima (rituximab), Herzuma (trastuzumab), and newer products like Vegzelma, Yuplima, Stelima, Stoboclo, Osenbelt, Omilclo, Aputozimab, and Ayden Jelt. The company also provides CMO services for both chemical (tablets, capsules) and biopharmaceutical (PFS, autoinjector) manufacturing, supported by globally certified production facilities. An E-Order system serves distributor logistics.

Product and service14 records
1Remsima (램시마주) - Infliximab Biosimilar
CategoryBiosimilar
2Remsima SC - Subcutaneous Infliximab Biosimilar
CategoryBiosimilar
3Truxima (트룩시마주) - Rituximab Biosimilar
CategoryBiosimilar
4Herzuma (허주마주) - Trastuzumab Biosimilar
CategoryBiosimilar
5Vegzelma (베그젤마) - Bevacizumab Biosimilar
CategoryBiosimilar
6Yuplima (유플라이마) - Secukinumab Biosimilar
CategoryBiosimilar
7Stoboclo (스토보클로) - Denosumab Biosimilar
CategoryBiosimilar
8Osenbelt (오센벨트) - Denosumab Biosimilar
CategoryBiosimilar
9Omilclo (옴리클로) - Omalizumab Biosimilar
CategoryBiosimilar
10Aputozimab (앱토즈마) - Tocilizumab Biosimilar
CategoryBiosimilar
11Stekima (스테키마) - Biosimilar
CategoryBiosimilar
12Idenzel (아이덴젤트) - Ophthalmic Biosimilar
CategoryBiosimilar
13Eptozma (엡토즈마) - Tocilizumab Biosimilar
CategoryBiosimilar
14Godex Capsule (고덱스캡슐) - Liver Disease Treatment
CategoryChemical Pharmaceutical
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Samsung Group-backed biosimilar developer commercializing multiple mAb biosimilars (Renflexis, Imraldi, Ontruzant, etc.) globally and in Korea. Direct head-to-head competitor across autoimmune and oncology biosimilar franchises in Korean hospitals.

TypeDirect peer
Description

Sister company within Celltrion Group that develops and globally commercializes the same biosimilar molecules (Remsima, Truxima, Herzuma) that Celltrion Pharm distributes in Korea. Closest comparable in therapeutic scope, but Celltrion Inc operates globally while Celltrion Pharm is Korea-only.

3GC Pharma (formerly Green Cross Corporation)
TypeDirect peer
Description

One of Korea's largest pharmaceutical companies with a broad biosimilar, blood plasma, and vaccine portfolio. Comparable in scale, business mix (biologics + small molecule), and Korean hospital-channel GTM.

4Alteogen
TypeDirect peer
Description

Korean biosimilar and biobetter developer with a pipeline targeting key mAb franchises. Competes directly for Korean biosimilar market share and has proprietary SC delivery technology (Hybrozyme) that parallels Celltrion Pharm's Remsima SC approach.

TypeDirect peer
Description

Major Korean pharma with biosimilars, innovative small molecules (HM-Brex, Efpegerglucagon), and proprietary drug delivery platforms. Comparable in mixed biologics/small-molecule strategy and Korean commercial focus.

TypeBroad incumbent
Description

World's largest biologics contract manufacturer by capacity. Comparable in biopharmaceutical manufacturing expertise, global GMP certifications, and PFS/aseptic fill-finish capability — but operates purely as a CDMO without proprietary commercial products.

TypeRegional player
Description

Mid-sized Korean pharma with strong small-molecule portfolio, biosimilars (DWP710001), and international expansion ambitions. Comparable as a domestic Korean pharma competitor in shared hospital channels.

TypeRegional player
Description

Korea's largest pharmaceutical company by sales, with a diversified branded generics and innovative drug portfolio. Comparable as a Korean-market pharma with similar NHI pricing exposure and hospital-channel commercial model.

TypeRegional player
Description

Long-established Korean pharma with branded small-molecule portfolio and growing biosimilar activities. Comparable as a domestic Korean pharma operating under the same NHI pricing regime.

TypeBroad incumbent
Description

Global biopharmaceutical leader that both develops reference biologics and markets biosimilars (Amgevita, Kanjinti). Comparable as a competitor and counterparty in the Korean biosimilar market, with broader global reach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celltrion Pharm

Biosimilar Pharmaceuticalscelltrionph.com

Celltrion Pharm is a South Korea-based, KOSDAQ-listed pharmaceutical manufacturer selling a portfolio of 12 biosimilars and chemical drugs to Korean hospitals, clinics, and pharmacies through medical representatives and distributors, supported by globally GMP-certified manufacturing facilities.

What Celltrion Pharm does

Celltrion Pharm, Inc. (셀트리온제약, KOSDAQ: KS200026) is a South Korea-based pharmaceutical manufacturer founded in 2000 and operating as a publicly listed subsidiary of Celltrion Group since 2009. The company produces and sells a portfolio of 12 biosimilar products and a broad line of chemical pharmaceuticals across autoimmune disease, oncology, allergy, liver disease, and cardiovascular therapeutic areas. Its flagship biosimilars include Remsima (world's first infliximab biosimilar), Remsima SC (world's first subcutaneous infliximab biosimilar), Truxima (rituximab), Herzuma (trastuzumab), and Vegzelma (bevacizumab); the chemical portfolio is anchored by Godex, the #1 outpatient liver-treatment brand in Korea. The company also operates a CMO business for oral solid dosage and PFS biopharmaceutical manufacturing under FDA, EMA, PMDA, and ANVISA GMP certifications.

Celltrion Pharm's technology platform spans biosimilar cell-line and process development, antibody-drug conjugate (ADC) research, subcutaneous and autoinjector formulation know-how, and nano/microsphere drug delivery systems. Manufacturing is concentrated at the GMP-certified Cheongju plant (OSD and PFS) and the Jincheon plant (chemical products), with research based at the Songdo Global Biotech Research Center. The company sells exclusively through Korean domestic channels — nine regional branch offices, medical representative coverage of hospitals and clinics, and a dedicated e-order system for registered pharmaceutical distributors — with end customers being healthcare providers and pharmacies whose purchases are reimbursed under the Korean National Health Insurance system.

In FY2025, Celltrion Pharm reported record revenue of 536.4 billion KRW, the first time the company exceeded 500 billion KRW in annual sales, supported by 1,006 employees. The company's commercial model is a sales-led enterprise field-sales motion with academic symposia, with revenue generated through prescription pharmaceutical sales, CMO services, and a regulated NHI pricing framework. Celltrion Group retains majority ownership and strategic oversight.

Celltrion Pharm firmographics

Firmographics
Name
Celltrion Pharm
Legal name
주식회사 셀트리온제약 (Celltrion Pharm, Inc.)
Website
https://celltrionph.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
101–250 employees
Short description
Celltrion Pharm is a South Korea-based, KOSDAQ-listed pharmaceutical manufacturer selling a portfolio of 12 biosimilars and chemical drugs to Korean hospitals, clinics, and pharmacies through medical representatives and distributors, supported by globally GMP-certified manufacturing facilities.
Ownership category
akta.pro rank

Celltrion Pharm industry classification

Industry
Product category
Biosimilar Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)

Keywords

  • Biosimilar pharmaceuticals
  • Chemical pharmaceuticals
  • Contract manufacturing
  • Drug delivery systems
  • Antibody drug conjugates

Where Celltrion Pharm is headquartered

Location

Headquarters

HQ city
Cheongju
HQ country
South Korea
HQ region
Asia

Offices5 records

Markets served

Celltrion Pharm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Technology or R&D, Marketing or Sales, Personnel

Revenue model

  1. Biosimilar Drug Sales: Sale of biosimilar pharmaceutical products including Remsima, Truxima, Herzuma, Vegzelma, Yuplima, and other autoimmune/cancer treatments in Korean domestic market
  2. Chemical Drug Sales: Sale of chemical pharmaceutical products including cardiovascular, endocrine, digestive, antibiotic treatments. Major product Godex leads liver treatment market. Achieved first 500 billion KRW annual sales milestone.
  3. CMO Services: Contract manufacturing services for OSD (oral solid dosage) and PFS (pre-filled syringe) formulations under global GMP standards for domestic and international partners

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goOmriqlo 150mg AI - same price as PFS formulation

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Celltrion Pharm product offering

Product offering

Core offering

Celltrion Pharm manufactures and sells biosimilar and chemical pharmaceutical products in the Korean domestic market, with a portfolio of 12 biosimilars (including Remsima, Truxima, Herzuma, Vegzelma) and chemical drugs (including Godex for liver disease and combination antihypertensives). The company also provides contract manufacturing (CMO) services for oral solid dosage (OSD) and pre-filled syringe (PFS) formulations to domestic and international pharmaceutical partners under global GMP standards.

Product overview

Celltrion Pharm is a Korean pharmaceutical company offering both chemical and biosimilar products, with a portfolio of 12 biosimilar products and diverse chemical medications across therapeutic areas including cardiovascular, endocrine, digestive, and liver diseases. The chemical portfolio includes market-leading products like Godex for liver disease and combination antihypertensives like Treble Tab and Idaldipine. The biosimilar portfolio features world-first antibody biosimilars including Remsima (infliximab), Truxima (rituximab), Herzuma (trastuzumab), and newer products like Vegzelma, Yuplima, Stelima, Stoboclo, Osenbelt, Omilclo, Aputozimab, and Ayden Jelt. The company also provides CMO services for both chemical (tablets, capsules) and biopharmaceutical (PFS, autoinjector) manufacturing, supported by globally certified production facilities. An E-Order system serves distributor logistics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Remsima (램시마주) - Infliximab Biosimilar
  • Remsima SC - Subcutaneous Infliximab Biosimilar
  • Truxima (트룩시마주) - Rituximab Biosimilar
  • Herzuma (허주마주) - Trastuzumab Biosimilar
  • Vegzelma (베그젤마) - Bevacizumab Biosimilar
  • Yuplima (유플라이마) - Secukinumab Biosimilar
  • Stoboclo (스토보클로) - Denosumab Biosimilar
  • Osenbelt (오센벨트) - Denosumab Biosimilar
  • Omilclo (옴리클로) - Omalizumab Biosimilar
  • Aputozimab (앱토즈마) - Tocilizumab Biosimilar
  • Stekima (스테키마) - Biosimilar
  • Idenzel (아이덴젤트) - Ophthalmic Biosimilar
  • Eptozma (엡토즈마) - Tocilizumab Biosimilar
  • Godex Capsule (고덱스캡슐) - Liver Disease Treatment

Quantifiable outcome

  • Remsima cumulative sales of 3,008 billion KRW as of December 2025
  • +2 more outcomes

Companies that use Celltrion Pharm

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Celltrion Pharm technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Celltrion Pharm partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Celltrion Pharm competitors and assessment

Company assessment

Direct peers

  • Samsung Bioepis: Samsung Group-backed biosimilar developer commercializing multiple mAb biosimilars (Renflexis, Imraldi, Ontruzant, etc.) globally and in Korea. Direct head-to-head competitor across autoimmune and oncology biosimilar franchises in Korean hospitals.
  • Celltrion Inc. Sister company within Celltrion Group that develops and globally commercializes the same biosimilar molecules (Remsima, Truxima, Herzuma) that Celltrion Pharm distributes in Korea. Closest comparable in therapeutic scope, but Celltrion Inc operates globally while Celltrion Pharm is Korea-only.
  • GC Pharma (formerly Green Cross Corporation): One of Korea's largest pharmaceutical companies with a broad biosimilar, blood plasma, and vaccine portfolio. Comparable in scale, business mix (biologics + small molecule), and Korean hospital-channel GTM.
  • Alteogen: Korean biosimilar and biobetter developer with a pipeline targeting key mAb franchises. Competes directly for Korean biosimilar market share and has proprietary SC delivery technology (Hybrozyme) that parallels Celltrion Pharm's Remsima SC approach.
  • Hanmi Pharmaceutical: Major Korean pharma with biosimilars, innovative small molecules (HM-Brex, Efpegerglucagon), and proprietary drug delivery platforms. Comparable in mixed biologics/small-molecule strategy and Korean commercial focus.

Broad incumbents

  • Samsung Biologics: World's largest biologics contract manufacturer by capacity. Comparable in biopharmaceutical manufacturing expertise, global GMP certifications, and PFS/aseptic fill-finish capability — but operates purely as a CDMO without proprietary commercial products.
  • Amgen: Global biopharmaceutical leader that both develops reference biologics and markets biosimilars (Amgevita, Kanjinti). Comparable as a competitor and counterparty in the Korean biosimilar market, with broader global reach.

Regional players

  • Daewoong Pharmaceutical: Mid-sized Korean pharma with strong small-molecule portfolio, biosimilars (DWP710001), and international expansion ambitions. Comparable as a domestic Korean pharma competitor in shared hospital channels.
  • Yuhan Corporation: Korea's largest pharmaceutical company by sales, with a diversified branded generics and innovative drug portfolio. Comparable as a Korean-market pharma with similar NHI pricing exposure and hospital-channel commercial model.
  • Dong-A Pharmaceutical: Long-established Korean pharma with branded small-molecule portfolio and growing biosimilar activities. Comparable as a domestic Korean pharma operating under the same NHI pricing regime.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Celltrion Pharm social profiles

Digital presence

Celltrion Pharm compliance and trust

Trust signal

Compliance9 records

Celltrion Pharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celltrion Pharm leadership team

Management profile

Number of profiles

Profiles8 records

Celltrion Pharm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celltrion Pharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celltrion Pharm

What does Celltrion Pharm do?

Celltrion Pharm manufactures and sells biosimilar and chemical pharmaceutical products in the Korean domestic market, with a portfolio of 12 biosimilars (including Remsima, Truxima, Herzuma, Vegzelma) and chemical drugs (including Godex for liver disease and combination antihypertensives). The company also provides contract manufacturing (CMO) services for oral solid dosage (OSD) and pre-filled syringe (PFS) formulations to domestic and international pharmaceutical partners under global GMP standards.

Is Celltrion Pharm a public or private company?

Celltrion Pharm is a public company. It is classified as public and is currently operating.

When was Celltrion Pharm founded?

Celltrion Pharm was founded in 2000. It employs 101 to 250 people.

Where is Celltrion Pharm based?

Celltrion Pharm is headquartered in Cheongju, South Korea, in the Asia region.

How does Celltrion Pharm make money?

Three revenue lines are on record. Biosimilar Drug Sales are the primary driver. The others are chemical Drug Sales and CMO Services.

Who are Celltrion Pharm's main competitors?

Direct peers on record are Samsung Bioepis, Celltrion Inc., GC Pharma (formerly Green Cross Corporation), Alteogen and Hanmi Pharmaceutical. Broad incumbents are Samsung Biologics and Amgen. Regional players are Daewoong Pharmaceutical, Yuhan Corporation and Dong-A Pharmaceutical.

Does Celltrion Pharm have an API?

No public API is recorded for Celltrion Pharm.

What industry is Celltrion Pharm in?

Celltrion Pharm's product category is Biosimilar Pharmaceuticals. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NateCelltrion Pharmaceutical, Q2 operating profit of 19.3 billion 'the largest quarterly' : Nate NewsCelltrion Pharmaceutical reported record-breaking Q2 2026 earnings with operating profit of 19.3 billion KRW, driven by expanded prescriptions of biosimilar drugs and increased CMO production volumes. The company achieved double-digit operating margin of 12.6% with sales growing 16.8% year-on-year to 153.3 billion KRW. Key products including autoimmune treatments Yuflyma and Stelima, along with 53.4% growth in CMO business, powered the all-time high quarterly performance.NateCelltrion Pharmaceutical invests 2 trillion won in PFS production facility in the Chungcheong region: Nate NewsCelltrion Pharmaceutical announced a 2 trillion won investment to establish a pre-filled syringe (PFS) production facility in the Chungbuk region, with the first phase of 1 trillion won allocated for construction starting in 2028 and operations targeted by 2032. The investment will expand the company's PFS production capacity from 20 million to 70 million syringes per year, creating a one-stop production system covering preparation, aseptic filling, assembly, and packaging. A potential second phase of investment, also around 1 trillion won, will be considered based on global market demand for biopharmaceuticals and self-injection products.NateSamsung, SK, and others receive 392 trillion investment in Chungcheong 'one-stop support for land, power, and water': Nate NewsSamsung and SK received a combined 392 trillion won investment commitment for advanced industries in South Korea's Chungcheong region, with local governments welcoming the announcement as a major economic boost. SK Hynix plans to invest 100 trillion won in NAND flash manufacturing in Cheongju, while Celltrion Pharmaceutical committed over 2 trillion won for pharmaceutical facilities and Samsung Electro-Mechanics over 8 trillion won in Sejong. Chungnam Province will form a task force with investing companies to provide expedited administrative support, citing the region's existing infrastructure as enabling rapid production and export capabilities.ChosunbizCelltrion Pharm boosts Q2 profit by 64.8% driven by strong biosimilar salesCelltrion Pharm reported Q2 revenue of 131.3 billion won, up 12.1% year-on-year, and operating profit of 15.5 billion won, up 64.8%. Biosimilar revenue rose 58.3% to 32.5 billion won, and the company plans to expand biosimilar production and contract manufacturing.ChosunbizCelltrion Pharm achieves record revenue of 477.8 billion won with strong R&D growthCelltrion Pharm reported record annual sales of 477.8 billion won, up 22.9% year-over-year, with operating profit of 37.2 billion won. Growth was driven by key products like Godekse and new biosimilars, including Remsima SC and Uplima. The company plans to expand sales and invest in R&D for new products.The Korea HeraldCelltrion creates holding company for 3-away mergerCelltrion Group announced the creation of Celltrion Healthcare Holdings as a step toward merging Celltrion, Celltrion Pharma, and Celltrion Healthcare by end-2021. Chairman Seo Jung-jin's stake in Celltrion Healthcare fell from 35.54% to 11.21% after he sold shares to form the holding company. The merger aims to streamline operations and prepare for his planned exit.The Korea HeraldAmid continued selling spree, foreign investors eye Celltrion sharesForeign investors bought 427 billion won of Celltrion's affiliates, with Celltrion Pharm leading at 291.1 billion won net purchase. The stock price spiked 35.6% during the period, and analysts cite potential COVID-19 cure and Takeda acquisition as drivers.